ERBB2 and cancer: Importantly, these findings have clinical relevance given that different therapies may benefit patients with HER2-zero cancer (treatments other than HER2-targeted therapies), HER2-low cancer (novel anti-HER2 drugs), and HER2-positive cancer (traditional anti-HER2 medications).